Souhaitez-vous accéder aux communiqués récents ?

Freiburg, den 7. Mai 2025 Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes Arzneimittel...

Freiburg, May 7th, 2025 Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary...

Positive data from the Phase 2 SPRING trial of nebokitug in PSC was presented in an oral Distinguished Abstract Plenary session at DDW 2025

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.

Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.

After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.

Chemomab will present at the Oppenheimer Heathcare Life Sciences Conference on Feb 11 at 8 am ET and participate in 1x1 investor meetings.

Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC

Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.